Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barbara Burtness MD

Barbara Burtness MD

Anthony N. Brady Professor of Medicine; Chief Translational Research Officer; Associate Director, Translational Science; Chief, Head and Neck Cancers/Sarcoma; Co-Leader, Developmental Therapeutics Program; Director, Yale Head and Neck SPORE, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut

Dr. Barbara Burtness is Anthony N. Brady Professor of Medicine at the Yale University School of Medicine. She is founding director of the Yale Head and Neck SPORE, co-leader of the Developmental Therapeutics Program, and director of the Head and Neck Clinical Research Program at Yale Cancer Center.

Dr. Burtness’s research focuses on clinical trials of immunotherapy and translational studies of resistance to immunotherapy and EGFR inhibition, and synthetic lethal approaches for HPV-negative head and neck cancer. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multicenter trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers, and she co-leads the Stand Up to Cancer Head and Neck Cancer Team.

Dr. Burtness co-edits the text Molecular Determinants of Head and Neck Cancer. Her research has been published in numerous peer-reviewed journals, including The Lancet, Journal of Clinical Oncology, The Lancet Oncology, and Clinical Cancer Research.

Disclosures

  • Honoraria/Consulting/Data Safety Monitoring Boards: AbbVie, ALX Oncology, Astra Zeneca, Coherus, Cue Biopharma, Eisai, Glaxo Smith Kline, IMS Consulting, IO Biotech, Kura, Merck KgaA, Merck, Merus, Orphagen, Vaccinex, Slingshot Bio, Surface

Recent Contributions to PracticeUpdate:

  1. ASCO: Tumor Mutational Burden in HPV-Negative Head and Neck Cancer
  2. ASCO: Transoral Robotic Surgery Followed by Low or Standard Dose Radiation for p16+ Oropharyngeal Cancer
  3. ASCO: Progression After Next Line of Therapy Following First-Line Immunotherapy for Advanced Head and Neck Cancer
  4. PD-1 Blockade in Anaplastic Thyroid Carcinoma
  5. Integrating Post-Radiotherapy Plasma EBV DNA and TNM Stage for Risk Stratification of Nasopharyngeal Carcinoma to Adjuvant Therapy
  6. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer
  7. An Overview of Immunotherapy in Head and Neck Cancer
  8. Current Perspectives on HPV+ Head and Neck Cancer
  9. 2019 Top Stories in Oncology: First-Line Pembrolizumab in Metastatic or Recurrent HNSCC
  10. Brachytherapy in Patients With Oral Cavity and Oropharyngeal Cancer

Most Read This Week

Recently Updated